Abstract
Huntington's disease (HD) is a neurodegenerative disease for which there is no cure. Therapies that are efficacious in animal models have to date shown benefit for humans. One potential powerful approach is gene therapy. The ideal method of administration of gene therapy has been hotly debated and viral vectors have provided one method of long-term and wide-spread delivery to the brain. Trophic factors to protect cells from degeneration and RNAi to reduce mutant huntingtin (mHtt) protein expression are 2 main classes of compounds that demonstrate benefit in animal models. This review will examine some commonly used adeno-associated viral (AAV) vectors and discuss some therapies that hold promise for HD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 243-254 |
| Number of pages | 12 |
| Journal | Neurobiology of Disease |
| Volume | 48 |
| Issue number | 2 |
| DOIs | |
| State | Published - Nov 2012 |
| Externally published | Yes |
Keywords
- Adeno-associated viral (AAV) vectors
- Allele-specific RNAi
- Brain-derived neurotrophic factor (BDNF)
- Ciliary neurotrophic factor (CNTF)
- GFL
- Gene therapy
- Glial cell line-derived neurotrophic factor (GDNF)
- Intrabody therapy
- Neurturin (NRTN)
- Nonallele-specific RNAi
- Oligonucleotides
- Pseudotypes
- RNA interference (RNAi)
- Serotype
ASJC Scopus subject areas
- Neurology